跳到正文
原文
Medical Xpress·· 23 天前精选AI 评分65

²¹²Pb-ADVC001 I 期试验:alpha 核素疗法在晚期前列腺癌中未出现剂量限制性毒性

Novel alpha radiopharmaceutical therapy shows promise in early-phase prostate cancer trial

AI 导读

TheraPb I 期首次人体试验显示,alpha 核素疗法 ²¹²Pb-ADVC001 用于既往接受过雄激素受体通路抑制剂和紫杉类化疗的 PSMA 阳性转移性前列腺癌患者,未观察到剂量限制性毒性,最大耐受剂量未达到。

推荐理由

I 期剂量递增试验给出安全性与 PSA 反应数据,可了解 alpha 核素在前列腺癌治疗中的早期剂量选择依据。

正文
prostate cancer
Credit: Anna Tarazevich from Pexels

A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting toxicities observed, and showed encouraging signs of antitumor activity, according to a trial published in The Journal of Nuclear Medicine's Late-Breaking Fast Track.

Among patients treated with ²¹²Pb-ADVC001, 80% experienced a decline in prostate-specific antigen (PSA) levels of at least 50%, and the overall response rate was 100%. The findings support further clinical development of ²¹²Pb-ADVC001 to address the unmet needs in metastatic prostate cancer.

Prostate-specific membrane antigen (PSMA)–targeted RPT is an established treatment for metastatic androgen pathway modulation-resistant prostate cancer (mAPM-R, formerly metastatic castration-resistant prostate cancer). Although ¹⁷⁷Lu-PSMA-617, a beta-emitting RPT, has shown improved overall and radiographic progression-free survival in pivotal trials, approximately one-third of patients are resistant to ¹⁷⁷Lu-PSMA, and most responders progress during or soon after treatment.

"Current RPTs use fixed dosing regimens that do not account for variability in tumor response," said the study authors. "These limitations highlight the need for novel treatment strategies that may enhance patient outcomes using more potent payloads and optimization of dose and schedule."

Late-breaking: Novel alpha radiopharmaceutical therapy shows promising activity in phase 1 prostate cancer trial
TheraPb study design and results. Credit: SNMMI.

Alpha-emitting RPTs have emerged as a new treatment approach: unlike beta emitters such as ¹⁷⁷Lu, which release lower-energy particles that travel up to a couple of millimeters, alpha emitters release high-energy particles that travel only a few cell widths, delivering concentrated radiation to cancer cells while sparing surrounding healthy tissue.

The TheraPb Phase I trial, a first-in-human study, evaluated both escalating doses and dosing frequency of the alpha-targeting RPT ²¹²Pb-ADVC001.

The study included 22 participants with progressive mAPM-R previously treated with an androgen-receptor pathway inhibitor and taxane chemotherapy. Escalating doses of 60–200 MBq of ²¹²Pb-ADVC001 were administered at prespecified intervals every six, four, two or one week for up to six doses across seven dose-schedule cohorts.

Researchers examined dose-limiting toxicities and adverse events to recommend doses for a Phase II trial. They also evaluated PSA response, radiographic progression-free survival and overall response rate.

No dose-limiting toxicities were observed, and the maximum tolerated dose was not reached. The most common treatment-related adverse events were dry mouth and nausea, and no serious adverse events occurred. Given these findings, the study committee selected 160 and 200 MBq as the recommended doses for Phase II of TheraPb.

In this early-phase study, 80% of participants had a PSA decline of 50% or more, and the median radiographic progression-free survival was 11.2 months. The overall response rate was 100%.

"Flexibility in dosing, together with the overall safety profile of ²¹²Pb-ADVC001, further provides a rationale for evaluating combination strategies with other anticancer agents to maximize clinical outcomes," stated the authors.

Publication details

Aaron R. Hansen et al., TheraPb Phase 1b: First-in-Human Dose-Escalation and Optimization Study of 212Pb-ADVC001 in PSMA-Positive Metastatic Androgen Pathway Modulation–Resistant Prostate Cancer, Journal of Nuclear Medicine (2026). DOI: 10.2967/jnumed.126.274089

Journal information: Journal of Nuclear Medicine

Who's behind this story?

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Novel alpha radiopharmaceutical therapy shows promise in early-phase prostate cancer trial (2026, October 27) retrieved 27 October 2026 from https://medicalxpress.com/news/2026-10-alpha-radiopharmaceutical-therapy-early-phase.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com